FDA Approves Kirsty As First Interchangeable Insulin Aspart Biosimilar

July 15, 2025

The FDA approves Kirsty, the first interchangeable insulin aspart biosimilar, enhancing access to affordable diabetes care for millions.

White Paper Offers Tips for Sustaining Biosimilar Progress, Avoiding a Market Void

July 15, 2025

BioRationality: How the FDA Can Bypass Congress to Change Biosimilar Guidance

July 14, 2025

Balancing Cost Savings With Clinical Practice for Multiple Myeloma Biosimilars: Tyler Sandahl, PharmD

July 14, 2025

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11, 2025

The Top 5 Biosimilar Articles for the Week of June 5

June 9th 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of June 5, 2023.

Medicare 340B Program May Be Reducing Biosimilar Uptake

June 8th 2023

By Laura Joszt

Article

New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.

Dr Fran Gregory Discusses the Future Landscape of the Biosimilars Marketplace

June 7th 2023

By Pearl Steinzor

Video

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what the future biosimilars marketplace may look like compared with generics and reference products at Asembia 2023.

Spain Could Save Millions With Greater Bevacizumab Biosimilar Adoption

June 5th 2023

By Justina Petrullo

Article

If biosimilars are introduced to Spain, they will most likely save money in the pharmacological budget, according to a budget impact analysis model.

Biosimilars Immunology Roundup for May 2023—Podcast Edition

June 4th 2023

By Justina Petrullo

Podcast

On this episode of Not So Different, we recap some of the biggest stories in the immunology space regarding biosimilars, including a new European approval, ustekinumab biosimilar delays, and more.

Alvotech, Advanz Pharma Extend Partnership for Biosimilars in Europe

June 3rd 2023

By Skylar Jeremias

Article

Alvotech and Advanz Pharma extend their partnership to commercialize 5 biosimilar candidates across Europe.

The Top 5 Biosimilar Articles for the Week of May 29

June 2nd 2023

By Justina Petrullo

Video

Here are the top 5 biosimilar articles for the week of May 29, 2023.

Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar

June 1st 2023

By Skylar Jeremias

Article

The Mark Cuban Cost Plus Drug Company, an online pharmacy dedicated to increasing access to lower-cost prescriptions, is partnering with Coherus Biosciences to distribute Yusimry, a biosimilar referencing Humira. It’s the first time the pharmacy has added a biosimilar to its list of drugs.

Biosimilars Immunology Roundup: May 2023

June 1st 2023

By Skylar Jeremias

Article

Over the course of May, the immunology biosimilar space bloomed, with a European approval, a delay for ustekinumab biosimilars, more clinical trial updates, and insights into the industry from multiple immunology experts.

Samsung Bioepis' Eculizumab Biosimilar Approved in Europe

May 31st 2023

By Skylar Jeremias

Article

The European Commission has granted marketing authorization to Samsung Bioepis' biosimilar referencing Soliris (eculizumab). The product, dubbed Epysqli, is the first hematology biosimilar from Samsung Bioepis to be approved in the European Union.